Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979552860> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2979552860 abstract "Abstract Background Interim results from the ongoing, 2-cohort, phase 2 KEYNOTE-100 study (NCT02674061) have suggested clinical efficacy of pembrolizumab (pembro) monotherapy in some patients (pts) with advanced ovarian cancer (AOC). Here, we present efficacy and safety results from Japanese pts in KEYNOTE-100. Methods Pts with epithelial AOC, fallopian tube cancer, or primary peritoneal cancer with prior treatment with debulking surgery followed by front-line platinum-based chemotherapy (CT) and documented disease recurrence were eligible for this study. Cohort A received ≤2 prior CT lines and had a platinum- or treatment-free interval (PFI; TFI) of 3-12 months. Cohort B received 3-5 prior CT lines and had a PFI/TFI of ≥ 3 months. All pts received pembro 200 mg every 3 weeks as monotherapy for 2 years or until progression, death, unacceptable toxicity, or consent withdrawal. The primary objectives were ORR per RECIST v1.1 by blinded independent central review for each cohort and by tumor PD-L1 expression. The relationship between PD-L1 expression (defined as combined positive score [CPS]) and ORR was assessed. Results In the second interim analysis (Matalounis, ASCO 2018) of the overall study population (N = 376), the ORR in Cohort A and B were 7% (95% CI, 5-11; n = 285) and 10% (95% CI, 5-18; n = 91), respectively. 21 Japanese pts were treated (19 in Cohort A; 2 in Cohort B). Mean (SD) age was 57 (10) years; 91% had ECOG PS 0, and 76% had stage 3-4 disease. The ORR in all pts was 19% (95% CI, 5-42). ORR increased with increasing PD-L1 expression: 25% (2/8) with CPS ≥1 and 50% (1/2) with CPS ≥10. 62% of pts had treatment-related adverse events (TRAEs), and 24% had grade 3-5 TRAEs. There were no treatment-related deaths in this subpopulation. Conclusion Pembro monotherapy was associated with antitumor activity in Japanese pts with recurrent AOC, with no new safety signals identified in this subpopulation. There was a potential trend associated with ORR and PD-L1 expression." @default.
- W2979552860 created "2019-10-18" @default.
- W2979552860 creator A5001446997 @default.
- W2979552860 creator A5010757746 @default.
- W2979552860 creator A5013258133 @default.
- W2979552860 creator A5025271372 @default.
- W2979552860 creator A5025940379 @default.
- W2979552860 creator A5038498441 @default.
- W2979552860 creator A5040103958 @default.
- W2979552860 creator A5043373703 @default.
- W2979552860 creator A5052576209 @default.
- W2979552860 creator A5054335379 @default.
- W2979552860 creator A5058249824 @default.
- W2979552860 creator A5062470926 @default.
- W2979552860 creator A5066133616 @default.
- W2979552860 creator A5068679494 @default.
- W2979552860 creator A5072348132 @default.
- W2979552860 creator A5077255843 @default.
- W2979552860 creator A5085728973 @default.
- W2979552860 creator A5089095204 @default.
- W2979552860 date "2019-10-01" @default.
- W2979552860 modified "2023-09-27" @default.
- W2979552860 title "KN100: Results from Japanese patients with advanced recurrent ovarian cancer treated with pembrolizumab monotherapy" @default.
- W2979552860 doi "https://doi.org/10.1093/annonc/mdz374.004" @default.
- W2979552860 hasPublicationYear "2019" @default.
- W2979552860 type Work @default.
- W2979552860 sameAs 2979552860 @default.
- W2979552860 citedByCount "0" @default.
- W2979552860 crossrefType "journal-article" @default.
- W2979552860 hasAuthorship W2979552860A5001446997 @default.
- W2979552860 hasAuthorship W2979552860A5010757746 @default.
- W2979552860 hasAuthorship W2979552860A5013258133 @default.
- W2979552860 hasAuthorship W2979552860A5025271372 @default.
- W2979552860 hasAuthorship W2979552860A5025940379 @default.
- W2979552860 hasAuthorship W2979552860A5038498441 @default.
- W2979552860 hasAuthorship W2979552860A5040103958 @default.
- W2979552860 hasAuthorship W2979552860A5043373703 @default.
- W2979552860 hasAuthorship W2979552860A5052576209 @default.
- W2979552860 hasAuthorship W2979552860A5054335379 @default.
- W2979552860 hasAuthorship W2979552860A5058249824 @default.
- W2979552860 hasAuthorship W2979552860A5062470926 @default.
- W2979552860 hasAuthorship W2979552860A5066133616 @default.
- W2979552860 hasAuthorship W2979552860A5068679494 @default.
- W2979552860 hasAuthorship W2979552860A5072348132 @default.
- W2979552860 hasAuthorship W2979552860A5077255843 @default.
- W2979552860 hasAuthorship W2979552860A5085728973 @default.
- W2979552860 hasAuthorship W2979552860A5089095204 @default.
- W2979552860 hasConcept C121608353 @default.
- W2979552860 hasConcept C126322002 @default.
- W2979552860 hasConcept C141071460 @default.
- W2979552860 hasConcept C143998085 @default.
- W2979552860 hasConcept C2777701055 @default.
- W2979552860 hasConcept C2780057760 @default.
- W2979552860 hasConcept C2780427987 @default.
- W2979552860 hasConcept C2781100745 @default.
- W2979552860 hasConcept C2908647359 @default.
- W2979552860 hasConcept C535046627 @default.
- W2979552860 hasConcept C61943457 @default.
- W2979552860 hasConcept C71924100 @default.
- W2979552860 hasConcept C72563966 @default.
- W2979552860 hasConcept C99454951 @default.
- W2979552860 hasConceptScore W2979552860C121608353 @default.
- W2979552860 hasConceptScore W2979552860C126322002 @default.
- W2979552860 hasConceptScore W2979552860C141071460 @default.
- W2979552860 hasConceptScore W2979552860C143998085 @default.
- W2979552860 hasConceptScore W2979552860C2777701055 @default.
- W2979552860 hasConceptScore W2979552860C2780057760 @default.
- W2979552860 hasConceptScore W2979552860C2780427987 @default.
- W2979552860 hasConceptScore W2979552860C2781100745 @default.
- W2979552860 hasConceptScore W2979552860C2908647359 @default.
- W2979552860 hasConceptScore W2979552860C535046627 @default.
- W2979552860 hasConceptScore W2979552860C61943457 @default.
- W2979552860 hasConceptScore W2979552860C71924100 @default.
- W2979552860 hasConceptScore W2979552860C72563966 @default.
- W2979552860 hasConceptScore W2979552860C99454951 @default.
- W2979552860 hasLocation W29795528601 @default.
- W2979552860 hasOpenAccess W2979552860 @default.
- W2979552860 hasPrimaryLocation W29795528601 @default.
- W2979552860 hasRelatedWork W14127037 @default.
- W2979552860 hasRelatedWork W1743485 @default.
- W2979552860 hasRelatedWork W17587699 @default.
- W2979552860 hasRelatedWork W18373595 @default.
- W2979552860 hasRelatedWork W19985250 @default.
- W2979552860 hasRelatedWork W2880624 @default.
- W2979552860 hasRelatedWork W370487 @default.
- W2979552860 hasRelatedWork W7720014 @default.
- W2979552860 hasRelatedWork W8076426 @default.
- W2979552860 hasRelatedWork W4714080 @default.
- W2979552860 isParatext "false" @default.
- W2979552860 isRetracted "false" @default.
- W2979552860 magId "2979552860" @default.
- W2979552860 workType "article" @default.